A local “AntiCov Nasal Spray”, developed by researchers from five medical departments, is expected to launch in the market in the third quarter of 2022, giving alternatives to prevent the spread of the Covid-19 Coronavirus.
Associate Professor Chanchai Sittipunt of the Faculty of Medicine, Chulalongkorn University, told the Associated Press today, February 28th, that the research team, including researchers from Chulalongkorn University, Silpakorn University, Health Systems Research Institute (HSRI), Government Pharmaceutical Organization (GPO), and Hibiocy Company Limited, had been incubating and developing antibodies that have antimicrobial elements to prevent the spread of the Covid-19 infection since the beginning of the outbreak.
A prototype antibody is now used in the medical development of the nasal spray with Covid-19 antibodies and is now proposed for a patent license to drive further research and development of Thai innovations to an international standard.
The relevant agencies would conduct clinical research and produce the spray in line with the standards before registering with the Thai Food and Drug Administration (FDA) around June 2022. It was expected to be released into the market around the third quarter this year for Thai people to have access to alternative health innovations to prevent the spread of Covid-19 and to cope with the pandemic situation.
Dr. Phaporn Prasitdamrong, Director of the Hibiocy Company Limited, added that the company continued to support the research and production of the medicine and they also planned to expand the product to the international market to promote Thai innovation to the global stage as well.
Photo Courtesy: Government Pharmaceutical Organization (GPO)
Follow us on Facebook